00:48 , May 17, 2019 |  BC Innovations  |  Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

Model-informed drug development is poised to move into personalized dosing, with a little help from exosomes. An August FDA workshop aims to shed light on when and how to use these precision dosing models in...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

PGXL Laboratories, SureGene LLC sales and marketing update

SureGene and partner PGXL launched the SureGene Test for Antipsychotic and Antidepressant Response (STA2R) in the U.S. The pharmacogenetic test combines the SULT4A1 genetic signature with four other tests for serotonin (5-HT) transporter ( SLC6A4...
07:00 , Aug 4, 2011 |  BC Innovations  |  Tools & Techniques

Metabolically, man or mouse

Massachusetts researchers have created mice with human ectopic artificial livers that were used to evaluate human drug metabolism, drug-drug interactions and drug-induced liver injury in a proof-of-principle study. 1 Unlike animal models that are currently...
23:52 , Mar 25, 2011 |  BC Extra  |  Financial News

AssureRx raises $11 million in series B

AssureRx Health Inc. (Mason, Ohio) raised $11 million in a series B round co-led by Claremont Creek Ventures and Sequoia Capital. New investor Allos Ventures joined existing investors Cincinnati Children's Hospital; Mayo Clinic; and CincyTech...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Company News

AssureRx sales and marketing update

AssureRx updated its GeneSightRx test to include a sixth gene, cytochrome P450 family 2 subfamily C polypeptide 9 (CYP2C9) . Last year, the company updated the test to include cytochrome P450 family 1 subfamily A...
07:00 , Mar 15, 2010 |  BC Week In Review  |  Company News

AssureRx sales and marketing update

AssureRx updated its GeneSightRx test to include a fifth gene, cytochrome P450 family 1 subfamily A polypeptide 2 (CYP1A2) . Last year, the company launched the test, which already detects SNPs in the cytochrome P450...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Clinical News

Zanaflex tizanidine regulatory update

ACOR issued a "Dear Healthcare Professional" letter to update the contraindication and warning sections of the label for Zanaflex tizanidine to include results from a pharmacokinetic study showing interactions between the spasticity drug and the...
07:00 , May 7, 2001 |  BC Week In Review  |  Company News

Maxygen other research news

California Institute of Technology (Pasadena, Calif.) researchers published in Nature Biotechnology a method to create libraries by DNA shuffling for proteins with little sequence homology but similar 3-dimensional structures. Using SHIPREC, researchers created more soluble...